Pharmagreen Biotech Business Summary

Pharmagreen Biotech Inc. (PHBI) operates as a vertically integrated biotechnology and nutraceutical company specializing in the production of disease-free starter plantlets and high-purity botanical extracts. The company generates revenue through three primary channels: the direct-to-consumer sale of its proprietary MaxGenomic™ nutraceutical supplements via platforms like Amazon and Shopify, the licensing of its "Chibafreen" tissue culture technology for hemp and medical cannabis, and the provision of genetic selection consulting services. A significant 2026 growth driver is its "Live Rosin" project, which utilizes a solventless extraction process and Standard Organic Non-Spray Cultivation Procedures (SONSCP) to produce premium cannabis concentrates. Pharmagreen competes directly with specialized biotech and cannabis firms such as Bright Green Corporation (BGXX), Artelo Biosciences (ARTL), and SciSparc Ltd (SPRC), positioning itself as a high-tech niche player focused on genetic uniformity and pharmaceutical-grade botanical purity. The company is led by Peter Wojcik, who has served as CEO, President, and Sole Director since 2018; Wojcik is a major shareholder and the primary architect of the firm’s transition from a pure-play cannabis nursery to a diversified life sciences entity. Supporting the technical roadmap is Ethan Styles, appointed in late 2024 as Vice President of Product Research and Development, a legacy cultivator with extensive expertise in molecular biology and therapeutic plant formulations. Financial oversight is managed by Terry Kwan, the CFO of the company’s wholly-owned subsidiary, WFS Pharmagreen Inc. While the company maintains a lean internal structure, it is backed by institutional investor Vermögensclub and has historically leveraged strategic partnerships, such as its collaboration with sports ambassador Tyrell Crosby, to scale its wellness and active-lifestyle product lines.